Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Alzheimer's Drug Discovery Foundation (ADDF) has awarded $773,000 grant to Metabolic Solutions Development Company (MSDC) for conducting MSDC-0160 Phase 2a trial as a treatment for metabolic diseases linked with altered mitochondrial function.
Subscribe to our email newsletter
The placebo-controlled, double-blind Phase 2a study expects to include around 50 patients of age 55-85 who have been diagnosed with mild Alzheimer’s disease.
Currently, MSDC-0160 is being examined in 330 type 2 diabetes patients in a Phase 2b study across 26 sites in the US.
MSDC president and chief scientific officer Jerry Colca said MSDC-0160 is a novel insulin sensitizer that modulates mitochondrial metabolism.
"This study will help us determine if MSDC-0160 affects glucose utilization in specific regions of the brain and determine the feasibility of conducting future large-scale clinical studies in patients with mild Alzheimer’s disease," Colca said.